Introduction & rationale for the review
Objectives
Methods
Ethics and protocol registration
Criteria for considering studies for this review
Types of studies and participants
Types of interventions
Types of outcome measures
-
Symptom scores on the subjective feeling of nausea, measured by standardized scales or methods [e.g. Visual Analogue Scale (VAS)].
-
The incidence of vomiting episodes, measured by daily recording.
-
The general response to the treatment, measured by standardized scales or methods (e.g. the 5-point Likert-type scale).
-
The occurrence of adverse events and side-effects.
Search methods for identification of studies
Selection of studies
Data extraction and management
Assessment of quality of evidence
Measures of treatment effect and data synthesis
Subgroup and sensitivity analyses
Results
Study selection
Study characteristics
Study ID | Risk of bias | NPB/NME (treatment) | Intervention (ginger dose/day) | Comparator* (dose per day) | L of T (days) | Main outcome measures | Main results |
---|---|---|---|---|---|---|---|
High | 65/62 (32G, 30C) | Ginger biscuits (500 mg 5 times daily = 2500 mg/day) | Placebo biscuit (5 biscuits per day, dose not specified) | 4 | Severity of nausea (VAS 0–10); number of vomiting episodes; general response to treatment (5-item Likert scale) | Ginger biscuits provided significantly greater relief from the severity of nausea (p = 0.01), and to some extent vomiting (p = 0.24). | |
High | 126/123 (61G, 62C) | Ginger powder capsules (325 mg ×2, three times daily, = 1950 mg/day) | Vitamin B6 capsules (12.5 mg ×2, three times daily =75 mg/day) | 4 | Change in nausea and vomiting scores (3 symptoms on Rhodes index); occurrence of side-effects | Results showed that ginger is significantly more effective in relieving NVP than vitamin B6 (p < 0.05). | |
High | 70/69 (35G, 34C) | Ginger powder capsules (500 mg 2×/d =1000 mg/day) | Vitamin B6 capsules (20 mg twice per day =40 mg/day) | 4 | Severity of nausea (VAS 0–10); number of vomiting episodes; general response to treatment (5-item Likert scale); occurrence of side-effects or adverse pregnancy outcome | The results showed that the ginger is significantly more effective than vitamin B6 for relieving the severity of nausea (p < 0.024), and equally effective for reducing the number of vomiting episodes. | |
Mode-rate | 30/27 (27G, 27C) (cross-over**) | Ginger powder capsules (250 mg 4 times per day = 1000 mg/day) | Placebo capsules (lactose) (250 mg 4 times per day = 1000 mg/day) | 4 | Preference of treatment period; relief scores (4-point scoring system); outcome of pregnancy | The results showed that ginger was significantly more effective than the placebo in eliminating or minimizing HG (p = 0.035). | |
High | 26/21 (12G, 9C) | Ginger syrup in water (250 mg 4 times per day = 1000 mg/day) | Placebo syrup (lemon oil) 4x/day (dose not specified) | 14 | Level of nausea (numerical scale 1–10); number of vomiting episodes | Ginger had a greater effect on the relieving of NVP, but due to the small study sample the results were not statistically analyzed. The authors concluded that ginger syrup may be more effective than placebo syrup in treatment of NVP. | |
High | 102/102 (34G, 34C1, 34C2) | Ginger essence capsules (200 mg 3×/day = 600 mg/day) |
1. Metoclopramide capsules (10 mg 3×/day = 30 mg/day) | 5 | Used RINVR to measure severity of nausea and vomiting. | Ginger was less effective than metoclopramide in reducing nausea and vomiting during pregnancy, but the difference was not statistically significant (p = 0.509). | |
2. Placebo capsules (flour) (200 mg 3×/day = 600 mg/day) | |||||||
Mode-rate | 70/67 (32G, 53C) | Ginger powder capsules (250 mg 4 times per day = 1000 mg/day) | Placebo capsules (lactose) (250 mg 4 ×/d 1000 mg/day) | 4 | Nausea intensity (VAS 0–10); number of vomiting incidences | The results showed that ginger was significantly more effective than the placebo in improving symptoms of NVP (p < 0.05). | |
High | 170/151 (77G, 74C) | Ginger powder capsules (500 mg 2x/d =1000 mg/day) | Dimenhydrinate capsules (50 mg 2x/d = 100 mg/day) | 7 | Degree of nausea (VAS 0–10); number of vomiting incidences; occurrence of side-effects | There was no significant difference in the visual analogue nausea scores between the two groups. Ginger was as effective as dimenhydrinate in the treatment of NVP, and has fewer side-effects. | |
High | 291/235 (120G, 115C) | Ginger capsules (350 mg 3times per day = 1050 mg/day) | Vitamin B6 capsules (25 mg 3x/d =75 mg/day) | 21 | Nausea, vomiting and dry retching on days 0,7,14,21 (Rhodes Index of Nausea and Vomiting Form2) (5-point Likert scale); change in health status on day 0,21 (MOS 36 Short Form Health Survey, 8-multi-item scale, higher core = better outcome); occurrence of side-effects and adverse pregnancy outcomes | The results indicated that ginger is equivalent to vitamin B6 in improving nausea, dry retching and vomiting in pregnancy. All p-values were <0.001. | |
High | 138/128 (64G, 64C) | Ginger powder capsules (500 mg 3×/d 1500 mg/day) | Vitamin B6 capsules (10 mg 3×/d =30 mg/day) | 3 | Severity of nausea (VAS 0–10); number of vomiting incidences; occurrence of side-effects | Both ginger and vitamin B6 were effective for treating NVP (p < 0.001). There were no significant differences between the two treatments’ efficacy. | |
High | 70/67 (32G, 35C) | Ginger powder capsules (250 mg 4x/day =1000 mg/day) | Placebo capsules (not specified) (250 mg 4x/day = 1000 mg/day) | 4 | Severity of nausea (VAS 0–10); number of vomiting episodes; general response to treatment after 1 week (5-item Likert scale); occurrence of side-effects and adverse pregnancy outcomes | Ginger was significantly more effective than the placebo in relieving the severity of nausea in pregnancy (p = 0.014). | |
Mode-rate | 120/99 (48G, 51C) | Ginger extract capsules (125 mg 4x/d =1000 mg/day) | Placebo capsules (soy bean oil 4x/d) (dose not specified) | 4 | Used RINVR to measure frequency, duration, distress caused by nausea, vomiting and retching; long term follow-up for birth outcome | Ginger was more effective than placebo for improving nausea and retching during pregnancy, but no difference in the vomiting episodes were observed. No p-values were provided. |
Characteristics of outcome measures
General response to treatment
Adverse events and side-effects
Methodological quality
Effect of interventions
Comparison 1: Ginger versus Placebo
Improvement in nausea symptoms
Reduction in the number of vomiting episodes
General response to treatment
The occurrence of adverse events and side effects
Outcome | Number of studies | RR | 95% CI | Heterogeneity | |
---|---|---|---|---|---|
Chi2
| I2(%) | ||||
Ginger versus placebo
| |||||
#Allergic reaction [30] | 1 | 3.00 | 0.12 to 72.20 | ||
#Dehydration [30] | 1 | 3.00 | 0.12 to 72.20 | ||
2 | 3.14 | 0.65 to 15.11 | 0.00 | 0 | |
Abdominal discomfort [29] | 1 | 3.27 | 0.14 to 77.57 | ||
Diarrhea [29] | 1 | 3.27 | 0.14 to 77.57 | ||
Drowsiness [29] | 1 | 2.82 | 0.12 to 66.62 | ||
Headache [29] | 1 | 1.31 | 0.44 to 3.89 | ||
3 | 5.03 | 0.89 to 28.61 | 0.35 | 0 | |
Worsening of symptoms requiring pharmaceutical treatment [30] | 1 | 0.33 | 0.01 to 8.02 | ||
Ginger versus vitamin B
6
| |||||
#Arrhythmia [20] | 1 | 0.51 | 0.05 to 5.46 | ||
2 | 0.49 | 0.17 to 1.42 | 1.67 | 40 | |
Belching [27] | 1 | 27.18 | 1.63 to 453.06* | ||
Burning sensation after capsule ingestion [27] | 1 | 1.01 | 0.21 to 4.91 | ||
2 | 0.75 | 0.48 to 1.19 | 0.18 | 0 | |
Dry retching [27] | 1 | 0.93 | 0.76 to 1.15 | ||
2 | 2.35 | 0.93 to 5.93 | 1.03 | 3 | |
Vomiting [27] | 1 | 1.51 | 0.26 to 8.91 | ||
Ginger versus Dimenhydrinate
| |||||
Drowsiness [26] | 1 | 0.08 | 0.03 to 0.18** | ||
Heartburn [26] | 1 | 1.44 | 0.65 to 3.20 |